RNAi for Therapeutic market was valued at US$ 258.3 million in 2022 and is anticipated to reach US$ 2218 million by 2029, witnessing a CAGR of 43.1% - valuates Reports

RNAi for Therapeutic market was valued at US$ 258.3 million in 2022 and is anticipated to reach US$ 2218 million by 2029, witnessing a CAGR of 43.1% during the forecast period 2023-2029.

Get sample report - https://reports.valuates.com/request/sample/QYRE-Auto-36L12811/Global_RNAi_for_Therapeutic_Sales_Market_Report_2023

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.
The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global RNAi for Therapeutic market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNAi for Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Segment by Type
siRNA
miRNA
shRNA

Segment by Application
Cancer
Cardiovascular
HBV
Others

Get detailed report - https://reports.valuates.com/market-reports/QYRE-Auto-36L12811/global-rnai-for-therapeutic-sales

Similar report -

https://reports.valuates.com/market-reports/QYRE-Auto-3J13439/global-antisense-and-rnai-therapeutics

https://reports.valuates.com/market-reports/ALLI-Auto-2Z585/nucleic-acid-therapeutics

https://reports.valuates.com/market-reports/QYRE-Auto-5B9421/global-synthetic-lethality-based-drugs-and-targets

Phone:
U.S. (TOLL FREE) : +1 (315) 215-3225
India: +91 8040957137

Email Id:
Please reach us at sales@valuates.com

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.